Stocks · News reference
Filed: 2026-08-26 AccNo: 0001140361-26-034401 Size: 7 MB Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
Reference details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Gyre Therapeutics (NASDAQ:GYRE) affirms FY2026 sales outlook from $100.500 million-$111.000 million to $100.500 million-$111.000 million vs $102.300 million estimate.
Read original at benzingaGyre Therapeutics (NASDAQ:GYRE) reported quarterly losses of $(0.12) per share which missed the analyst consensus estimate of $(0.04) by 200 percent. The company reported quarterly sales of $29.105 million which beat
Read original at benzingaFiled: 2026-07-15 AccNo: 0001140361-26-028564 Size: 2 MB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Read original at edgar